BioSpace News Archive

According to the latest research by Nova one advisor, the U.S. downstream processing market size was estimated at USD 12.90 billion in 2023 and it is projected to increase USD 49.53 billion by 2033 with a CAGR of 14.4% from 2024 to 2033.

Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on July 24, 2024, to all shareholders of record as of the close of business on July 2, 2024.

In the never ending quest for efficient cancer treatments, the evolving field has forced researchers to explore new avenues for taking on this aggressive illness.

Newtopia Inc. announced today that it will release combined financial results for the quarter ended December 31, 2023, and March 31, 2024, after market close on Thursday May 23rd, 2024.

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the third quarter of 2024.

Turn Therapeutics launched its first public investment campaign today to fund clinical trials of its Food and Drug Administration-cleared antimicrobial ointment for two potential new drug indications: moderate to severe eczema and onychomycosis, or toenail fungus.

Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted approval for the Company’s Abbreviated New Drug Application for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008.

Atea Pharmaceuticals, Inc. announced the Company will present new efficacy results, including SVR12 data, from the Phase 2 lead-in cohort evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus at the European Association for the Study of the Liver Congress 2024, taking place June 5-8, 2024 in Milan, Italy.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that dosing has been initiated in a Phase I study of the drug candidate IRL757.

Antion Biosciences, a Geneva-based cell and gene therapy company developing “off-the-shelf” cell therapies, announces the development of next generation anti-CD19 chimeric antigen receptor T-cells for B-cell driven autoimmune diseases.